Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Operating Profit Margin
since 2005

Microsoft Excel

Paying user area

Try for free

Regeneron Pharmaceuticals Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Regeneron Pharmaceuticals Inc., operating profit margin, long-term trends, calculation

Microsoft Excel
Operating profit margin = 100 × Income (loss) from operations1 ÷ Revenues1
Dec 31, 2025 = 100 × ÷
Dec 31, 2024 = 100 × ÷
Dec 31, 2023 = 100 × ÷
Dec 31, 2022 = 100 × ÷
Dec 31, 2021 = 100 × ÷
Dec 31, 2020 = 100 × ÷
Dec 31, 2019 = 100 × ÷
Dec 31, 2018 = 100 × ÷
Dec 31, 2017 = 100 × ÷
Dec 31, 2016 = 100 × ÷
Dec 31, 2015 = 100 × ÷
Dec 31, 2014 = 100 × ÷
Dec 31, 2013 = 100 × ÷
Dec 31, 2012 = 100 × ÷
Dec 31, 2011 = 100 × ÷
Dec 31, 2010 = 100 × ÷
Dec 31, 2009 = 100 × ÷
Dec 31, 2008 = 100 × ÷
Dec 31, 2007 = 100 × ÷
Dec 31, 2006 = 100 × ÷
Dec 31, 2005 = 100 × ÷

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands

The operating profit margin exhibited significant volatility between 2005 and 2025. Initially, the metric was substantially negative, indicating considerable operational losses. Over time, a clear progression towards profitability is observed, followed by periods of fluctuation.

Early Years (2005-2011)
From 2005 to 2011, the operating profit margin remained consistently negative. The magnitude of the losses decreased from -187.97% in 2005 to -46.02% in 2011, suggesting a gradual reduction in operational inefficiencies or increasing revenue relative to operating expenses. However, profitability was not yet achieved during this period.
Transition to Profitability (2012-2018)
A pivotal shift occurred in 2012, with the operating profit margin turning positive at 33.20%. This positive trend continued, with the margin increasing to 37.77% by 2018. This period demonstrates successful operational improvements and revenue growth exceeding operating costs. The highest margin within this timeframe was recorded in 2017 at 35.41% and 2018 at 37.77%.
Recent Fluctuations (2019-2025)
Following the peak in 2018, the operating profit margin experienced fluctuations. It decreased to 28.10% in 2019, then surged to 42.09% in 2020, followed by a decline to 30.85% in 2022 and 28.10% in 2023. The most recent year, 2025, shows a further decrease to 24.95%. This suggests increased cost pressures or a slowdown in revenue growth in recent years, despite generally high revenue figures.
Overall Trend
Despite the recent fluctuations, the overall trend indicates a substantial improvement in operational profitability over the two-decade period. The company transitioned from significant operational losses to consistent profitability, although maintaining a stable margin has proven challenging in the later years of the observed period. The substantial increase in revenue between 2020 and 2021 did not translate into a sustained increase in operating profit margin, indicating potential issues with cost control or shifts in product mix.

Comparison to Competitors

Regeneron Pharmaceuticals Inc., operating profit margin, long-term trends, comparison to competitors

Microsoft Excel
Regeneron Pharmaceuticals Inc. AbbVie Inc. Amgen Inc. Danaher Corp. Gilead Sciences Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 31, 2008
Dec 31, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).